<DOC>
	<DOCNO>NCT00313729</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well temozolomide work treat patient supratentorial low-grade glioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Low-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy temozolomide , define response rate ( complete partial response ) , patient supratentorial mixed low-grade glioma . Secondary - Assess safety profile temozolomide patient supratentorial low-grade glioma . - Assess time tumor progression patient treat temozolomide . OUTLINE : Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove supratentorial lowgrade ( grade II ) glioma follow histologic subtypes : Oligodendroglioma Astrocytoma Oligoastrocytoma Has undergone surgical resection biopsy within 35 day diagnosis lowgrade glioma Study treatment must begin 14 day 4 month surgical resection biopsy Evaluable disease gadoliniumMRI PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine &lt; 1.5 time upper limit normal ( ULN ) BUN &lt; 1.5 time ULN Bilirubin &lt; 1.5 time ULN SGOT &lt; 2.5 time ULN Alkaline phosphatase &lt; 2 time ULN Life expectancy &gt; 12 week No nonmalignant systemic disease result patient poor medical risk No acute infection require intravenous antibiotic No frequent vomit medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) No concurrent malignancy except surgically cure carcinoma situ cervix basal cell squamous cell carcinoma skin Prior malignancy must remission ≥ 5 year No know HIV positivity No AIDSrelated illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy , interstitial brachytherapy , radiosurgery lowgrade glioma No prior biological therapy chemotherapy lowgrade glioma No concurrent chemotherapy No concurrent radiotherapy biological therapy No concurrent prophylactic growth factor No concurrent epoetin alfa No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>